Kenza Health Hub logoGet Started

Table of contents

Therapeutic actionIndicationsForms and strengthsDose and durationContra-indications, adverse effects, precautions
1 May 2026Oral drugsSource update: September 2023

SOF/DCV Oral: Hepatitis C Regimens

Sofosbuvir and daclatasvir guidance for chronic hepatitis C across several genotypes and cirrhosis states.

Also searched as

SOF/DCV oralSofosbuvir/Daclatasvir
Prescription under medical supervision

Source reviewed

September 2023

Guide category

Oral drugs

Safety boundary

Prescription medicine information for clinician-guided use.

Kenza Health Hub presents this medicine page as structured health education. Check dose, route, interactions, pregnancy or breast-feeding considerations, and local protocol with a qualified clinician or pharmacist. Read our medical editorial policy.

This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.

Therapeutic action

Combination of two direct-acting antivirals: a NS5B polymerase inhibitor (sofosbuvir) and a NS5A inhibitor (daclatasvir).

Indications

Treatment of chronic hepatitis C.

Forms and strengths

  • 400 mg sofosbuvir/60 mg daclatasvir co-formulated tablet.

Dose and duration

Genotypes 1, 2, 4, 5, 6 without cirrhosis or with compensated cirrhosis and genotype 3 without cirrhosis

  • Adult: one 400 mg/60 mg tablet once daily for 12 weeks.

Genotype 3 with compensated cirrhosis or genotypes 1, 2, 3, 4, 5, 6 with decompensated cirrhosis

  • Adult: one 400 mg/60 mg tablet once daily for 24 weeks.

Contra-indications, adverse effects, precautions

  • Do not administer to patients with allergy to sofosbuvir or daclatasvir.
  • May cause fatigue, headache, insomnia, dizziness, gastrointestinal disturbances, and arthralgia.
  • Administer with caution to patients co-infected with hepatitis B virus because of the risk of HBV reactivation.
  • Do not combine with carbamazepine, phenobarbital, phenytoin, rifampicin, rifabutin, rifapentine, oral or injectable dexamethasone, or amiodarone.
  • Administer with caution and monitor combination with efavirenz, etravirine, nevirapine, clarithromycin, erythromycin, itraconazole, atazanavir/ritonavir, and digoxin.
  • Closely monitor blood glucose levels in patients with diabetes and adjust antidiabetic treatment if necessary.
  • Provide effective contraception in women of childbearing age.
  • Pregnancy and breast-feeding: contraindicated because safety is not established.
  • Tablets have a bitter taste and should be swallowed whole with meals.

Source

MSF Essential drugs practical guidelines (January 2026)

This page combines source-derived medicine reference sections with Kenza editorial context, while leaving out the Storage and Remarks sections from the source batch.

Rate this guide

Be the first to rate this guide.